Results through week 52 of the PaTHway trial confirm and extend previously published clinical trial data that demonstrate the ability of TransCon PTH to restore functions of PTH including the endogenous production of calcitriol and mobilization of calcium from the skeleton and reduce the symptom burden associated with hypoparathyroidism and improve physical functioning and well-being (13, 18, 19). Here, PTH is linked to hypoparathyroidism.